



## Clinical trial results:

### Randomized, Double-Blind, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small-Cell Lung Cancer (NSCLC)

Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines.

## Summary

EudraCT number	2011-003427-36
Trial protocol	DE CZ HU SK
Global end of trial date	30 September 2014

## Results information

Result version number	v1 (current)
This version publication date	24 July 2016
First version publication date	24 July 2016

## Trial information

### Trial identification

Sponsor protocol code	M10-898
-----------------------	---------

### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01560104
WHO universal trial number (UTN)	-

Notes:

## Sponsors

Sponsor organisation name	Abbvie Deutschland GmbH & Co.KG
Sponsor organisation address	AbbVie House, Vanwall Business Park, Maidenhead, Berkshire, United Kingdom, SL6-4UB
Public contact	Global Medical Information, AbbVie, 011 800-633-9110,
Scientific contact	Vincent Giranda, MD, AbbVie , Vincent.Giranda@Abbvie.com

Notes:

## Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	30 September 2014
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	30 September 2014
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To assess if the addition of oral veliparib to carboplatin and paclitaxel compared to carboplatin and paclitaxel alone in subjects with metastatic or advanced non-small cell lung cancer (NSCLC) will improve progression-free survival (PFS).

Protection of trial subjects:

All subjects entering the study had to sign an informed consent that was explained to them and questions encouraged.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	16 February 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Slovakia: 4
Country: Number of subjects enrolled	Czech Republic: 10
Country: Number of subjects enrolled	France: 9
Country: Number of subjects enrolled	Germany: 8
Country: Number of subjects enrolled	Hungary: 25
Country: Number of subjects enrolled	Canada: 11
Country: Number of subjects enrolled	Russian Federation: 56
Country: Number of subjects enrolled	United States: 37
Worldwide total number of subjects	160
EEA total number of subjects	56

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	92
From 65 to 84 years	68
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Adult subjects  $\geq 18$  years of age, with life expectancy  $> 12$  weeks (per investigator's clinical assessment), with confirmed metastatic or advanced NSCLC not amenable to surgical resection or radiation with curative intent, and who had not received prior anticancer therapy for their metastatic NSCLC were eligible to enroll.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Group 1: Placebo

Arm description:

Participants enrolled under the original protocol received placebo capsules twice a day (BID) on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m<sup>2</sup> administered intravenously (IV) on Day 3 of each 21-day cycle for up to 6 cycles.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Placebo capsules administered orally twice a day

Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Carboplatin was administered IV over approximately 15 to 30 minutes at (AUC 6 mg/mL/min)

Investigational medicinal product name	Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Paclitaxel was administered IV over 3 hours at a dose of 200 mg/m<sup>2</sup>.

<b>Arm title</b>	Group 1: Veliparib 80 mg
------------------	--------------------------

Arm description:

Participants enrolled under the original protocol received 80 mg veliparib capsules BID on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m<sup>2</sup> administered IV on Day 3 of each 21-day cycle for up to 6 cycles.

Arm type	Experimental
Investigational medicinal product name	Veliparib
Investigational medicinal product code	ABT-888
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Veliparib capsules administered orally twice a day

Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Carboplatin was administered IV over approximately 15 to 30 minutes at (AUC 6 mg/mL/min)

Investigational medicinal product name	Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Paclitaxel was administered IV over 3 hours at a dose of 200 mg/m<sup>2</sup>.

<b>Arm title</b>	Group 2: Placebo
------------------	------------------

Arm description:

Participants enrolled under protocol amendment 2 received placebo capsules twice a day (BID) on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m<sup>2</sup> administered IV on Day 3 of each 21-day cycle for up to 6 cycles.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Placebo capsules administered orally twice a day

Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Carboplatin was administered IV over approximately 15 to 30 minutes at (AUC 6 mg/mL/min)

<b>Arm title</b>	Group 2: Veliparib 120 mg
------------------	---------------------------

Arm description:

Participants enrolled under protocol amendment 2 received 120 mg veliparib capsules BID on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m<sup>2</sup> administered IV on Day 3 of each 21-day cycle for up to 6 cycles

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Veliparib
Investigational medicinal product code	ABT-888
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Veliparib capsules administered orally twice a day

Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Carboplatin was administered IV over approximately 15 to 30 minutes at (AUC 6 mg/mL/min)

Investigational medicinal product name	Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Paclitaxel was administered IV over 3 hours at a dose of 200 mg/m<sup>2</sup>.

<b>Number of subjects in period 1</b>	Group 1: Placebo	Group 1: Veliparib 80 mg	Group 2: Placebo
Started	1	1	53
Received Treatment	1	1	52
Completed	1	1	39
Not completed	0	0	14
Consent withdrawn by subject	-	-	4
Other	-	-	2
Adverse event	-	-	8
Sponsor discontinued study	-	-	-

<b>Number of subjects in period 1</b>	Group 2: Veliparib 120 mg
Started	105
Received Treatment	105
Completed	75
Not completed	30
Consent withdrawn by subject	10
Other	4
Adverse event	14
Sponsor discontinued study	2



## Baseline characteristics

### Reporting groups

Reporting group title	Group 1: Placebo
-----------------------	------------------

Reporting group description:

Participants enrolled under the original protocol received placebo capsules twice a day (BID) on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m<sup>2</sup> administered intravenously (IV) on Day 3 of each 21-day cycle for up to 6 cycles.

Reporting group title	Group 1: Veliparib 80 mg
-----------------------	--------------------------

Reporting group description:

Participants enrolled under the original protocol received 80 mg veliparib capsules BID on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m<sup>2</sup> administered IV on Day 3 of each 21-day cycle for up to 6 cycles.

Reporting group title	Group 2: Placebo
-----------------------	------------------

Reporting group description:

Participants enrolled under protocol amendment 2 received placebo capsules twice a day (BID) on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m<sup>2</sup> administered IV on Day 3 of each 21-day cycle for up to 6 cycles.

Reporting group title	Group 2: Veliparib 120 mg
-----------------------	---------------------------

Reporting group description:

Participants enrolled under protocol amendment 2 received 120 mg veliparib capsules BID on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m<sup>2</sup> administered IV on Day 3 of each 21-day cycle for up to 6 cycles

Reporting group values	Group 1: Placebo	Group 1: Veliparib 80 mg	Group 2: Placebo
Number of subjects	1	1	53
Age categorical Units: Subjects			
< 65 years	0	0	30
≥ 65 years	1	1	23
Gender categorical Units: Subjects			
Female	0	1	21
Male	1	0	32
Stratification Factor: Histology Units: Subjects			
Squamous cell	1	0	25
Non-squamous cell	0	1	28

Reporting group values	Group 2: Veliparib 120 mg	Total	
Number of subjects	105	160	
Age categorical Units: Subjects			
< 65 years	62	92	
≥ 65 years	43	68	
Gender categorical Units: Subjects			
Female	30	52	
Male	75	108	



Stratification Factor: Histology			
Units: Subjects			
Squamous cell	51	77	
Non-squamous cell	54	83	

## End points

### End points reporting groups

Reporting group title	Group 1: Placebo
Reporting group description: Participants enrolled under the original protocol received placebo capsules twice a day (BID) on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m <sup>2</sup> administered intravenously (IV) on Day 3 of each 21-day cycle for up to 6 cycles.	
Reporting group title	Group 1: Veliparib 80 mg
Reporting group description: Participants enrolled under the original protocol received 80 mg veliparib capsules BID on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m <sup>2</sup> administered IV on Day 3 of each 21-day cycle for up to 6 cycles.	
Reporting group title	Group 2: Placebo
Reporting group description: Participants enrolled under protocol amendment 2 received placebo capsules twice a day (BID) on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m <sup>2</sup> administered IV on Day 3 of each 21-day cycle for up to 6 cycles.	
Reporting group title	Group 2: Veliparib 120 mg
Reporting group description: Participants enrolled under protocol amendment 2 received 120 mg veliparib capsules BID on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m <sup>2</sup> administered IV on Day 3 of each 21-day cycle for up to 6 cycles	

### Primary: Progression-free Survival (PFS)

End point title	Progression-free Survival (PFS) <sup>[1]</sup>
End point description: Progression-free survival was defined as the time from the date that the subject was randomized to the date the subject experienced an event of disease progression (as determined by the central imaging center) or to the date of death (all causes of mortality) if disease progression was not reached. All events of disease progression occurring on or before the date of the 78th PFS event were included, regardless of whether the event occurred while the subject was still taking study drug or had previously discontinued study drug. If the subject did not have disease progression nor had the subject died, the subject's data were censored at the date of the last disease assessment. If a disease progression event occurred after a subject missed 2 or more consecutive disease progression assessments, this subject was censored at the last disease progression assessment prior to the missing assessments. Efficacy analyses were performed for Group 2 subjects only.	
End point type	Primary
End point timeframe: From randomization to the data cutoff at the 78th PFS event (18 July 2013)	

#### Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.  
Justification: Efficacy analyses were performed for Group 2 subjects only.

End point values	Group 2: Placebo	Group 2: Veliparib 120 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	53	105		
Units: days				
median (confidence interval 95%)	129 (93 to	176 (130 to		

## Statistical analyses

<b>Statistical analysis title</b>	Analysis of progression-free Survival
Statistical analysis description:	
Statistical significance was determined by a two-sided P value $\leq 0.05$ .	
Comparison groups	Group 2: Placebo v Group 2: Veliparib 120 mg
Number of subjects included in analysis	158
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.167 <sup>[2]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.722
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.453
upper limit	1.149

Notes:

[2] - Log-rank test stratified by histology (squamous cell versus non-squamous cell).

## Secondary: Overall Survival

End point title	Overall Survival <sup>[3]</sup>
End point description:	
Time to death for a given subject was defined as the number of days from the date that the subject was randomized to the date of the subject's death. All events of death were included, regardless of whether the event occurred while the subject was still taking study drug or after the subject discontinued study drug. If a subject had not died, the data were censored at the date when the subject was last known to be alive.	
End point type	Secondary

End point timeframe:

From randomization until end of study

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Efficacy analyses were performed for Group 2 subjects only.

End point values	Group 2: Placebo	Group 2: Veliparib 120 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	53	105		
Units: days				
median (confidence interval 95%)	277 (165 to 374)	357 (268 to 416)		

## Statistical analyses

<b>Statistical analysis title</b>	Analysis of Overall Survival
Comparison groups	Group 2: Placebo v Group 2: Veliparib 120 mg
Number of subjects included in analysis	158
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.266 <sup>[4]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.802
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.544
upper limit	1.183

Notes:

[4] - Log rank test stratified by histology (squamous cell versus non-squamous cell)

## Secondary: Objective Response Rate

End point title	Objective Response Rate <sup>[5]</sup>
End point description:	
Objective response rate was defined as the proportion of subjects with complete or partial response, as determined by the central imaging center per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. Confirmation was not required to determine objective response.	
End point type	Secondary

End point timeframe:

From randomization until the cut-off at the 78th PFS event (18 July 2013)

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Efficacy analyses were performed for Group 2 subjects only.

<b>End point values</b>	Group 2: Placebo	Group 2: Veliparib 120 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	53	105		
Units: percentage of participants				
number (confidence interval 95%)	32.1 (19.9 to 46.3)	32.4 (23.6 to 42.2)		

## Statistical analyses

<b>Statistical analysis title</b>	Analysis of Objective Response Rate
Comparison groups	Group 2: Placebo v Group 2: Veliparib 120 mg
Number of subjects included in analysis	158
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.992 <sup>[6]</sup>
Method	Cochran-Mantel-Haenszel

Notes:

[6] - P value is from Cochran-Mantel-Haenszel test stratified by histology (squamous cell versus non-squamous cell).

## Secondary: Duration of Overall Response

End point title	Duration of Overall Response <sup>[7]</sup>
-----------------	---

End point description:

The duration of overall response for a given subject was defined as the number of days from the day the criteria were met for complete response or partial response (whichever was recorded first) to the date that progressive disease was objectively documented (by the central imaging center). If a subject was still responding, the subject's data were censored at the date of the last available disease progression assessment.

"99999" indicates data that could not be estimated.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until the cut-off date of the 78th PFS event (18 July 2013)

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Efficacy analyses were performed for Group 2 subjects only.

End point values	Group 2: Placebo	Group 2: Veliparib 120 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	17	34		
Units: days				
median (confidence interval 95%)	130 (84 to 99999)	211 (137 to 212)		

## Statistical analyses

<b>Statistical analysis title</b>	Analysis of Duration of Response
Comparison groups	Group 2: Placebo v Group 2: Veliparib 120 mg
Number of subjects included in analysis	51
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.182 <sup>[8]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.474

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.158
upper limit	1.424

Notes:

[8] - Log-rank P value stratified by histology (squamous cell versus non-squamous cell).

## Secondary: Change from Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy 20 (QLQ-CIPN20)

End point title	Change from Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy 20 (QLQ-CIPN20) <sup>[9]</sup>
-----------------	--

End point description:

The impact of chemotherapy-induced neuropathy (CIPN) on quality of life was assessed with the EORTC QLQ CIPN20, a 20-item questionnaire module developed to evaluate various aspects of CIPN. Each item is measured on a Likert scale ranging from 1 (not at all) to 4 (very much). The overall score was linearly transformed to a 0 to 100 scale, with higher scores representing more complaints.

The mean change from baseline was calculated using an analysis of covariance (ANCOVA) model with treatment group as the factor and the corresponding baseline value as a covariate.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and every 3 weeks until end of study

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Efficacy analyses were performed for Group 2 subjects only.

End point values	Group 2: Placebo	Group 2: Veliparib 120 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	48	94		
Units: units on a scale				
least squares mean (confidence interval 95%)				
Cycle 2 Day 1 (N = 48, 94)	4.009 (1.2408 to 6.777)	4.413 (2.4348 to 6.3904)		
Cycle 3 Day 1 (N = 44, 85)	4.916 (1.5535 to 8.278)	6.555 (4.1365 to 8.973)		
Cycle 4 Day 1 (N = 39, 77)	8.414 (4.4077 to 12.4198)	6.767 (3.9161 to 9.6176)		
Cycle 5 Day 1 (N = 35, 67)	8.509 (4.5908 to 12.4274)	8.629 (5.7978 to 11.4611)		
Cycle 6 Day 1 (N = 29, 60)	10.942 (5.6451 to 16.2396)	12.321 (8.6382 to 16.0036)		
Cycle 7 Day 1 (N = 25, 52)	13.576 (7.4149 to 19.7367)	15.597 (11.325 to 19.8684)		
Cycle 8 Day 1 (N = 16, 41)	9.505 (1.2527 to 17.7569)	14.034 (8.9009 to 19.1678)		
Cycle 9 Day 1 (N = 16, 34)	5.452 (-2.1343 to 13.0386)	15.426 (10.2566 to 20.5955)		

Cycle 10 Day 1 (N = 9, 27)	9.854 (-0.966 to 20.6744)	15.19 (8.9632 to 21.4174)		
Cycle 11 day 1 (N = 9, 21)	3.72 (-3.7312 to 11.1718)	9.602 (4.7245 to 14.4801)		
Cycle 12 Day 1 (N = 8, 18)	11.223 (2.0688 to 20.377)	8.344 (2.255 to 14.4336)		
Cycle 13 Day 1 (N = 7, 12 )	3.487 (-5.4678 to 12.4409)	8.652 (1.8145 to 15.4905)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Grade 3 or 4 Treatment-Emergent Adverse Events of Peripheral Neuropathy

End point title	Number of Participants With Grade 3 or 4 Treatment-Emergent Adverse Events of Peripheral Neuropathy <sup>[10]</sup>
-----------------	---

End point description:

Chemotherapy-induced peripheral neuropathy was assessed by the investigator utilizing the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 grading for neuropathy.

Grade 3 or 4 treatment-emergent adverse events of peripheral neuropathy were identified based on a standardized Medical Dictionary for Regulatory Activities (SMQ) (broad search).

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 of each cycle and at the final visit

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Efficacy analyses were performed for Group 2 subjects only.

End point values	Group 2: Placebo	Group 2: Veliparib 120 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	52	105		
Units: participants	2	1		

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From first dose until 30 days after last dose. Median treatment duration was 42 days for Group 1 participants, 40.5 days for Group 2 placebo participants and 36 days for Group 2 veliparib participants.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.0
--------------------	------

### Reporting groups

Reporting group title	Group 1: Placebo
-----------------------	------------------

Reporting group description:

Participants enrolled under the original protocol received placebo capsules twice a day (BID) on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m<sup>2</sup> administered intravenously (IV) on Day 3 of each 21-day cycle for up to 6 cycles.

Reporting group title	Group 1: Veliparib 80 mg
-----------------------	--------------------------

Reporting group description:

Participants enrolled under the original protocol received 80 mg veliparib capsules BID on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m<sup>2</sup> administered IV on Day 3 of each 21-day cycle for up to 6 cycles.

Reporting group title	Group 2: Placebo
-----------------------	------------------

Reporting group description:

Participants enrolled under protocol amendment 2 received placebo capsules twice a day (BID) on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m<sup>2</sup> administered IV on Day 3 of each 21-day cycle for up to 6 cycles.

Reporting group title	Group 2: Veliparib 120 mg
-----------------------	---------------------------

Reporting group description:

Participants enrolled under protocol amendment 2 received 120 mg veliparib capsules BID on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m<sup>2</sup> administered IV on Day 3 of each 21-day cycle for up to 6 cycles

Serious adverse events	Group 1: Placebo	Group 1: Veliparib 80 mg	Group 2: Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	12 / 52 (23.08%)
number of deaths (all causes)	1	0	39
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant Neoplasm Progression			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Malignant Pleural Effusion			



subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Non-Small Cell Lung Cancer			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Embolism			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior Vena Cava Occlusion			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vena Cava Thrombosis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic Reaction			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug Hypersensitivity			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary Embolism			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pulmonary Haemorrhage			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Respiratory Distress			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory Failure			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Delirium			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Weight Decreased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute Myocardial Infarction			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cardiac Failure Congestive			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Ischaemic Stroke			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile Neutropenia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			

Colitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Enterocolitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal Haemorrhage			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Renal Failure			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal Failure Acute			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Lung Abscess			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perirectal Abscess			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Tract Infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Group 2: Veliparib 120 mg		
Total subjects affected by serious adverse events			
subjects affected / exposed	28 / 105 (26.67%)		
number of deaths (all causes)	74		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant Neoplasm Progression			

subjects affected / exposed	2 / 105 (1.90%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 2		
<b>Malignant Pleural Effusion</b>			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Non-Small Cell Lung Cancer</b>			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 2		
<b>Vascular disorders</b>			
<b>Embolism</b>			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Superior Vena Cava Occlusion</b>			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
<b>Vena Cava Thrombosis</b>			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>General disorders and administration site conditions</b>			
<b>Fatigue</b>			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Immune system disorders</b>			
<b>Anaphylactic Reaction</b>			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Drug Hypersensitivity			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pulmonary Embolism			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pulmonary Haemorrhage			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 2		
Respiratory Distress			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory Failure			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Psychiatric disorders			
Delirium			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Weight Decreased			

subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Cardiac disorders</b>			
Acute Myocardial Infarction			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac Failure Congestive			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Nervous system disorders</b>			
Ischaemic Stroke			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 1		
<b>Blood and lymphatic system disorders</b>			
Anaemia			
subjects affected / exposed	3 / 105 (2.86%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		
Febrile Neutropenia			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Leukopenia			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Neutropenia			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		



Thrombocytopenia			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Colitis			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Enterocolitis			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal Haemorrhage			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Nausea			
subjects affected / exposed	3 / 105 (2.86%)		
occurrences causally related to treatment / all	1 / 4		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Renal Failure			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal Failure Acute			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Infections and infestations Bronchitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 105 (1.90%) 0 / 2 0 / 0		
Lung Abscess subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 105 (0.95%) 0 / 1 0 / 0		
Perirectal Abscess subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 105 (0.95%) 0 / 1 0 / 0		
Pneumonia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 105 (0.95%) 0 / 1 0 / 0		
Sepsis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 105 (0.95%) 1 / 1 0 / 0		
Urinary Tract Infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 105 (0.00%) 0 / 0 0 / 0		
Metabolism and nutrition disorders Hyponatraemia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 105 (0.95%) 0 / 1 0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Group 1: Placebo	Group 1: Veliparib 80 mg	Group 2: Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 1 (100.00%)	1 / 1 (100.00%)	41 / 52 (78.85%)
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	2 / 52 (3.85%)
occurrences (all)	1	0	3
Fatigue			
subjects affected / exposed	1 / 1 (100.00%)	1 / 1 (100.00%)	13 / 52 (25.00%)
occurrences (all)	1	1	15
Mucosal Inflammation			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	3 / 52 (5.77%)
occurrences (all)	0	0	4
Oedema Peripheral			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	5 / 52 (9.62%)
occurrences (all)	1	0	5
Pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	3 / 52 (5.77%)
occurrences (all)	0	0	3
Pyrexia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	4 / 52 (7.69%)
occurrences (all)	0	0	5
Immune system disorders			
Drug Hypersensitivity			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	2 / 52 (3.85%)
occurrences (all)	0	0	3
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	8 / 52 (15.38%)
occurrences (all)	1	0	8
Dyspnoea			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	5 / 52 (9.62%)
occurrences (all)	1	0	6
Haemoptysis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1

Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	5 / 52 (9.62%)
occurrences (all)	0	0	5
Investigations			
Platelet Count Decreased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	3 / 52 (5.77%)
occurrences (all)	0	0	9
Weight Decreased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	2 / 52 (3.85%)
occurrences (all)	0	0	2
Cardiac disorders			
Cardiac Failure Congestive			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	3 / 52 (5.77%)
occurrences (all)	0	0	3
Dysgeusia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	2 / 52 (3.85%)
occurrences (all)	0	0	2
Headache			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	3 / 52 (5.77%)
occurrences (all)	0	0	3
Neuropathy Peripheral			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	13 / 52 (25.00%)
occurrences (all)	1	0	19
Paraesthesia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	3 / 52 (5.77%)
occurrences (all)	0	0	3
Peripheral Sensory Neuropathy			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	4 / 52 (7.69%)
occurrences (all)	1	0	7
Polyneuropathy			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	4 / 52 (7.69%)
occurrences (all)	0	0	5

Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	21 / 52 (40.38%)
occurrences (all)	1	0	36
Leukopenia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	1 / 1 (100.00%)	1 / 1 (100.00%)	15 / 52 (28.85%)
occurrences (all)	1	1	28
Thrombocytopenia			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	8 / 52 (15.38%)
occurrences (all)	0	1	16
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	7 / 52 (13.46%)
occurrences (all)	0	1	8
Diarrhoea			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	8 / 52 (15.38%)
occurrences (all)	1	0	9
Nausea			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	13 / 52 (25.00%)
occurrences (all)	0	1	18
Stomatitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	3 / 52 (5.77%)
occurrences (all)	0	0	3
Vomiting			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	5 / 52 (9.62%)
occurrences (all)	0	0	5
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	22 / 52 (42.31%)
occurrences (all)	0	1	26
Pruritus			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Rash			

subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	1 / 1 (100.00%) 1	2 / 52 (3.85%) 2
Rash Pruritic subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	1 / 1 (100.00%) 1	1 / 52 (1.92%) 1
Renal and urinary disorders Pollakiuria subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 1 (0.00%) 0	0 / 52 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	1 / 1 (100.00%) 1	7 / 52 (13.46%) 7
Back Pain subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	1 / 1 (100.00%) 1	3 / 52 (5.77%) 4
Bone Pain subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 1 (0.00%) 0	2 / 52 (3.85%) 2
Musculoskeletal Chest Pain subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	1 / 1 (100.00%) 1	0 / 52 (0.00%) 0
Musculoskeletal Pain subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	3 / 52 (5.77%) 4
Myalgia subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	4 / 52 (7.69%) 7
Pain In Extremity subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	6 / 52 (11.54%) 9
Infections and infestations Lobar Pneumonia subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 1 (0.00%) 0	1 / 52 (1.92%) 1
Respiratory Tract Infection			

subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 52 (0.00%)
occurrences (all)	0	1	0
Urinary Tract Infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	3 / 52 (5.77%)
occurrences (all)	0	0	3
Metabolism and nutrition disorders			
Decreased Appetite			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	9 / 52 (17.31%)
occurrences (all)	0	0	12
Hyperglycaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	2 / 52 (3.85%)
occurrences (all)	0	0	3
Hyperkalaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	3 / 52 (5.77%)
occurrences (all)	0	0	3
Hypokalaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	4 / 52 (7.69%)
occurrences (all)	0	0	5
Hypomagnesaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	4 / 52 (7.69%)
occurrences (all)	0	0	8
Hyponatraemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	4 / 52 (7.69%)
occurrences (all)	0	0	6

<b>Non-serious adverse events</b>	Group 2: Veliparib 120 mg		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	92 / 105 (87.62%)		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	9 / 105 (8.57%)		
occurrences (all)	13		
Fatigue			
subjects affected / exposed	23 / 105 (21.90%)		
occurrences (all)	39		
Mucosal Inflammation			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Oedema Peripheral</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pyrexia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 105 (0.95%)</p> <p>3</p> <p>6 / 105 (5.71%)</p> <p>10</p> <p>2 / 105 (1.90%)</p> <p>3</p> <p>5 / 105 (4.76%)</p> <p>6</p>		
<p>Immune system disorders</p> <p>Drug Hypersensitivity</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>8 / 105 (7.62%)</p> <p>9</p>		
<p>Respiratory, thoracic and mediastinal disorders</p> <p>Cough</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dyspnoea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Haemoptysis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>8 / 105 (7.62%)</p> <p>9</p> <p>15 / 105 (14.29%)</p> <p>17</p> <p>6 / 105 (5.71%)</p> <p>7</p>		
<p>Psychiatric disorders</p> <p>Insomnia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>10 / 105 (9.52%)</p> <p>13</p>		
<p>Investigations</p> <p>Platelet Count Decreased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Weight Decreased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 105 (3.81%)</p> <p>5</p> <p>7 / 105 (6.67%)</p> <p>8</p>		



Cardiac disorders			
Cardiac Failure Congestive			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Dizziness			
subjects affected / exposed	7 / 105 (6.67%)		
occurrences (all)	9		
Dysgeusia			
subjects affected / exposed	6 / 105 (5.71%)		
occurrences (all)	7		
Headache			
subjects affected / exposed	8 / 105 (7.62%)		
occurrences (all)	10		
Neuropathy Peripheral			
subjects affected / exposed	25 / 105 (23.81%)		
occurrences (all)	38		
Paraesthesia			
subjects affected / exposed	4 / 105 (3.81%)		
occurrences (all)	6		
Peripheral Sensory Neuropathy			
subjects affected / exposed	8 / 105 (7.62%)		
occurrences (all)	13		
Polyneuropathy			
subjects affected / exposed	3 / 105 (2.86%)		
occurrences (all)	4		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	30 / 105 (28.57%)		
occurrences (all)	44		
Leukopenia			
subjects affected / exposed	10 / 105 (9.52%)		
occurrences (all)	13		
Neutropenia			
subjects affected / exposed	37 / 105 (35.24%)		
occurrences (all)	55		
Thrombocytopenia			

subjects affected / exposed	11 / 105 (10.48%)		
occurrences (all)	20		
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	9 / 105 (8.57%)		
occurrences (all)	12		
Diarrhoea			
subjects affected / exposed	13 / 105 (12.38%)		
occurrences (all)	16		
Nausea			
subjects affected / exposed	26 / 105 (24.76%)		
occurrences (all)	42		
Stomatitis			
subjects affected / exposed	3 / 105 (2.86%)		
occurrences (all)	3		
Vomiting			
subjects affected / exposed	5 / 105 (4.76%)		
occurrences (all)	5		
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	41 / 105 (39.05%)		
occurrences (all)	50		
Pruritus			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Rash			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Rash Pruritic			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Pollakiuria			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	20 / 105 (19.05%)		
occurrences (all)	31		
Back Pain			
subjects affected / exposed	8 / 105 (7.62%)		
occurrences (all)	8		
Bone Pain			
subjects affected / exposed	5 / 105 (4.76%)		
occurrences (all)	9		
Musculoskeletal Chest Pain			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences (all)	3		
Musculoskeletal Pain			
subjects affected / exposed	4 / 105 (3.81%)		
occurrences (all)	5		
Myalgia			
subjects affected / exposed	13 / 105 (12.38%)		
occurrences (all)	29		
Pain In Extremity			
subjects affected / exposed	12 / 105 (11.43%)		
occurrences (all)	14		
Infections and infestations			
Lobar Pneumonia			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences (all)	0		
Respiratory Tract Infection			
subjects affected / exposed	4 / 105 (3.81%)		
occurrences (all)	4		
Urinary Tract Infection			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences (all)	2		
Metabolism and nutrition disorders			
Decreased Appetite			
subjects affected / exposed	14 / 105 (13.33%)		
occurrences (all)	19		
Hyperglycaemia			

subjects affected / exposed	6 / 105 (5.71%)		
occurrences (all)	8		
Hyperkalaemia			
subjects affected / exposed	5 / 105 (4.76%)		
occurrences (all)	7		
Hypokalaemia			
subjects affected / exposed	6 / 105 (5.71%)		
occurrences (all)	6		
Hypomagnesaemia			
subjects affected / exposed	10 / 105 (9.52%)		
occurrences (all)	12		
Hyponatraemia			
subjects affected / exposed	5 / 105 (4.76%)		
occurrences (all)	7		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 February 2012	<p>The primary purpose of this amendment was to update the recommended Phase 2 dose to 120 mg BID veliparib after reviewing recent data from Studies GOG 9923 and CTEP 7967. The 120 mg BID dose of veliparib was determined to be the recommended Phase 2 dose based on data from Study GOG 9923 (Phase 1 dose-escalation study in subjects with advanced or metastatic ovarian cancer). Changes included the following:</p> <ul style="list-style-type: none"><li>• Updated veliparib/placebo dose to 120 mg BID throughout the protocol. Subjects enrolled under the original protocol received a starting dose of 80 mg BID veliparib/placebo and subjects enrolled under Amendment No. 1 were to receive a starting dose of 120 mg BID veliparib/placebo.</li><li>• Clarified Section 3.5, Study Rationale, and Section 5.6.4, Selection of Doses in the Study, to substantiate the rationale for selecting the 120 mg BID veliparib/placebo dose.</li><li>• Revised details of the IDMC safety review.</li><li>• Veliparib/placebo dose reduction guidelines were added in Section 5.7 for subjects starting at 120 mg BID veliparib/placebo.</li><li>• Revised the approximate number of subjects enrolled to 135 across approximately 50 sites.</li><li>• Added further detail to Section 5.2.3.2, Concomitant Therapy.</li><li>• Clarified several study activities in Table 2 (Study Activities).</li><li>• Added a complete blood count draw on C1D17.</li><li>• Corrected timing of serum pregnancy test to 14 days prior to C1D1 to clarify previous inconsistency within the protocol.</li><li>• Added clarification to the smoking status definitions for stratification.</li></ul>
29 April 2013	<p>The primary purpose of this amendment was to increase enrollment to approximately 150 subjects. Due to the number of progression events reported by investigators in the study thus far, the target sample size was increased to maintain timing of the efficacy and safety evaluation that was to commence once 78 PFS events had been observed. Additional changes included:</p> <ul style="list-style-type: none"><li>• Updated AbbVie medical monitor contact.</li><li>• Updated Section 3.4.3, Toxicology to reflect the most current data.</li><li>• Revised visit schedule for subjects who stopped treatment or completed maximum number of treatment cycles prior to reaching an event of disease progression from every 3 weeks to every 6 weeks.</li><li>• Added request for an unscheduled tumor assessment to be performed if the investigator anticipated subject discontinuation for a reason other than radiographic progression (unless a scan had been performed within the last 2 weeks).</li><li>• Added footnote to Table 3 regarding the archived tissue sample collection time to reflect corresponding lab manual.</li><li>• Updated Section 5.2.3.2, Concomitant Therapy to clarify excluded radiation therapy.</li><li>• Revised Section 5.3.1.3, Blood Samples for Pharmacodynamic Analyses to allow for cytology sample collection in certain cases where there was no archived tissue sample available.</li><li>• Clarification that subsequent IDMC meetings could have been requested by AbbVie (as indicated in the IDMC charter).</li><li>• Added guidance to Section 5.7.1 for subjects who commenced a cycle but could not receive chemotherapy on Day 3 due to an adverse event.</li><li>• Added clarifications throughout Section 8.0, Statistical Methods and Determination of Sample Size.</li><li>• Changed all instances of Abbott or Abbott Laboratories found within the protocol to AbbVie except if outside documents were referenced (e.g., Investigator's Brochure, references).</li><li>• Changed the manufacturer of drug supply in Section 5.5.2, Table 6, Identity of Investigational Product from Abbott to AbbVie/Abbott.</li></ul>

---

Notes:

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported